Sickle Cell Disease
L-Glutamine oral treatment with or without hydroxyurea reduces pain crises better than placebo in individuals with sickle cell disease.
In adults with sickle cell disease, higher daily opioid use may be associated with poorer health-related quality of life.
In this meta-analysis of prospective population-based studies, sickle cell trait was not associated with any difference in risk of first ischemic stroke.
Treatment with high-dose crizanlizumab resulted in an annual rate of sickle cell-related pain crises that was 45.3% lower compared with placebo.